Advanced Search

 

Study ID Status Title Patient Level Data
HS210915 Completed An open-label, multiple-dose, multicenter, pharmacokinetic, safety and tolerability study of valaciclovir oral suspension in infants and children with HSV infection Study Listed on ClinicalStudyDataRequest.com
HS210916 Completed An open-label, multiple-dose, multicenter, pharmacokinetic, safety and tolerability study of valaciclovir oral suspension in infants and children with VZV infection Study Listed on ClinicalStudyDataRequest.com
HS230018 Completed An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression of Recurrent Ano-Genital HSV Infections in HIV-Infected Subjects Study Listed on ClinicalStudyDataRequest.com
HS230027 Completed A Multicenter, Double-Blind, Placebo-Controlled Evaluation of Valaciclovir for the Reduction of the Length of Cold Sore Episodes Study Listed on ClinicalStudyDataRequest.com
HS230028 Completed A Multicenter, Double-Blind, Placebo-Controlled Evaluation of Valaciclovir for the Prevention/Blockage of the Progression of Cold Sore Lesion Development Study Listed on ClinicalStudyDataRequest.com
HS240017 Completed A Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate Daily Suppressive Therapy With VALTREX™ on the Rate of HSV Shedding in Subjects With Recurrent Genital Herpes Study Listed on ClinicalStudyDataRequest.com
HS240018 Completed A Randomized, Double-Blind, Multicenter Study of VALTREX 500mg Suppressive Therapy in the Reduction of Anxiety Associated with Recurrent Genital Herpes Study Listed on ClinicalStudyDataRequest.com
HS240021 Completed A Randomized, Double-Blind, Multicenter Study of VALTREX 500mg Suppressive Therapy in the Reduction of Anxiety Associated with Recurrent Genital Herpes Study Listed on ClinicalStudyDataRequest.com
HS2AB3009 Completed A Randomized, Double-Blind, Placebo-Controlled Evaluation of Valaciclovir for the Prevention of Herpes Simplex Virus (HSV) Transmission in Heterosexual Couples (Double-Blind Phase and Open-Label Suppression Phase) Study Listed on ClinicalStudyDataRequest.com
HZA102928 Completed A randomised, double blind, placebo controlled, parallel group, 14 day repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled GW685698X containing magnesium stearate in healthy subjects Study Listed on ClinicalStudyDataRequest.com
HZA102940 Completed A randomised, double-blind, placebo-controlled, four-way crossover study to compare the pharmacodynamics and pharmacokinetics of GW685698X and GW642444M when administered separately and in combination as a single dose from a novel dry powder device in healthy japanese subjects Study Listed on ClinicalStudyDataRequest.com
HZA105871 Completed A randomised, double-blind, placebo-controlled, four-way crossover study to compare the pharmacodynamics and pharmacokinetics of GW685698X and GW642444M when administered separately and in combination as a single dose from a novel dry powder device in healthy subjects Study Listed on ClinicalStudyDataRequest.com
HZA108799 Completed A randomised, double blind, two-way crossover study, to examine the safety, tolerability, pharmacokinetics and pharmacodynamics of a single inhaled administration of GW685698X (800 mcg) with and without magnesium stearate, in mild/moderate asthmatic patients. Study Listed on ClinicalStudyDataRequest.com
HZA109895 Terminated An exploratory study to evaluate the response of salmeterol plus fluticasone vs fluticasone alone to experimental nasal inoculation with rhinovirus Study Listed on ClinicalStudyDataRequest.com
HZA109912 Completed A 12-week, randomised, double-blind, placebo-controlled, three-period, cross-over pilot study comparing the effect of salmeterol/fluticasone propionate, fluticasone propionate and placebo on perpheral blood eosinophils and serum IL-5 in response to allergen challenge in asthma subjects when allergen challenge is administered at 1 hour or 11-12 hours post-dose of the dosing interval Study Listed on ClinicalStudyDataRequest.com
HZC111348 Completed Study HZC111348, a repeat-dose study of GW685698/GW642444 Inhalation Powder versus Placebo in the Treatment of Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
IDB-200-001 Completed A Randomized, Double-Blind Trial Evaluating the Safety and Immunogenicity of an Influenza Vaccine with reduced Preservative (FluLaval™ TR) and a Standard Influenza Vaccine (Fluarix®) in subjects between 18-60 and Over 60 Years of Age. Study Listed on ClinicalStudyDataRequest.com
ILI105618 Completed A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 (SB-485232) Administered by Intravenous Infusion in Combinationwith Rituximab in Adult Patients with B Cell Non-Hodgkin'sLymphoma" Study Listed on ClinicalStudyDataRequest.com
ILI108621 Completed A phase I, dose escalation study to assess the safety & biological activity of Interleukin 18 (SB-485232) administered by IV infusion in combination with pegylated liposomal doxorubicin (Doxil) in advanced stage epithelial ovarian cancer Study Listed on ClinicalStudyDataRequest.com
IPR110723 Completed An 8 day, randomised, double blind, 3-way crossover trial of repeat doses of intranasal GSK256066 and fluticasone propionate in the Vienna Challenge Chamber in subjects with seasonal allergic rhinitis (SAR) Study Listed on ClinicalStudyDataRequest.com
JNAI-01 Completed A Placebo-Controlled Study to Evaluate the Efficacy and Safety of Zanamivir 10 mg for Inhalation or Zanamivir 10 mg for inhalation plus Zanamivir 6.4 mg nasal spray, administered twice daily for 5 days, in the Treatment of Influenza A and B Viral Infections
JNAI-04 Completed A Placebo-Controlled Study to Evaluate the Efficacy and Safety of Zanamivir 10 mg administered Twice Daily (20 mg/day) or 20 mg Twice Daily (40 mg/day) for 5 Days in the Treatment of Influenza A and B Viral Infections, and to Assess the Presence or Absence of Dose-Response Relationship of Zanamivir
JNAI-07 Completed A Double -Blind, Placebo-Controlled Study to Investigate the Therapeutic Effect and Safety of Zanamivir 10 mg Administered Twice Daily (20 mg/day) or 20 mg Administered Twice Daily (40 mg/day) for Five Days in the Treatment of Influenza A and B Infections
KGW111083 Completed A double-blind, randomized, 6-sequence, 3-period crossover drug-drug interaction study to evaluate the pharmacokinetics of WELLBUTRIN SR (bupropion) and GSK189075 when co-administered or administered alone in healthy male volunteers
L8518 Completed Flexibility in administration of Arixtra for prevention of symptomatic venous thromboembolism in orthopedic surgery

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.